MetLife Investment Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-4,432
| Closed | -$181K | – | 2941 |
|
|
2024
Q2 | $181K | Sell |
4,432
-32,096
| -88% | -$1.31M | ﹤0.01% | 2315 |
|
|
2024
Q1 | $1.54M | Sell |
36,528
-254
| -0.7% | -$10.7K | 0.01% | 1068 |
|
|
2023
Q4 | $1.56M | Buy |
36,782
+3,996
| +12% | +$169K | 0.01% | 1068 |
|
|
2023
Q3 | $716K | Hold |
32,786
| – | – | 0.01% | 1417 |
|
|
2023
Q2 | $1.04M | Buy |
32,786
+2,367
| +8% | +$75.2K | 0.01% | 1247 |
|
|
2023
Q1 | $742K | Hold |
30,419
| – | – | 0.01% | 1398 |
|
|
2022
Q4 | $959K | Buy |
30,419
+1,578
| +5% | +$49.8K | 0.01% | 1233 |
|
|
2022
Q3 | $815K | Hold |
28,841
| – | – | 0.01% | 1295 |
|
|
2022
Q2 | $763K | Buy |
28,841
+3,683
| +15% | +$97.4K | 0.01% | 1367 |
|
|
2022
Q1 | $881K | Buy |
25,158
+9,285
| +58% | +$325K | 0.01% | 1411 |
|
|
2021
Q4 | $515K | Hold |
15,873
| – | – | ﹤0.01% | 1491 |
|
|
2021
Q3 | $468K | Hold |
15,873
| – | – | ﹤0.01% | 1555 |
|
|
2021
Q2 | $407K | Buy |
+15,873
| New | +$407K | ﹤0.01% | 1695 |
|